Indications for use:
Diabetes mellitus, type I (insulin-dependent); diabetes mellitus, type II (insulin-independent): the stage of resistance (resistance) to oral (taken by mouth) hypoglycemic (blood sugar lowering) agents, partial resistance to these products (combination therapy), intercurrent (complicating the course of diabetes mellitus) diseases, operations (monotherapy / treatment with one product / or combination therapy), pregnancy (if diet therapy is ineffective).
An insulin preparation based on recombinant DNA and identical to human insulin. Refers to long-acting products. The beginning of action – 4 hours. The maximum effect is 8-24 hours. Duration of action – 28 hours.
Ultratard HM (Ultratard nm) method of administration and doses: The
dose of the product is set by the doctor individually in each case, depending on the severity of the course of the disease. In its pure form, the product is administered 1-2 times a day only deep subcutaneously.
Before use, the contents of the vial are gently mixed until the solution is homogeneous. The required dose is immediately drawn into the syringe and an injection is made.
In type I diabetes, it is used as a basal insulin in combination with a fast-acting insulin product. In type II diabetes, it can be used both as monotherapy and in combination with fast-acting products.
When transferring patients from highly purified porcine insulin to human insulin, the dose remains the same. When transferring from bovine or mixed (porcine / bovine) insulin, the dose may be reduced by 10%, unless the initial dose is less than 0.6 U / kg of body weight.
At a daily dose exceeding 0.6 U/kg of body weight, insulin must be administered as 2 injections at different sites.
Patients receiving 100 IU or more per day, it is advisable to hospitalize for the time of changing insulin.
The change of insulin must be carried out under the control of blood glucose levels.
The need for the product may increase during illness, stress, when taken simultaneously with oral contraceptives, corticosteroids, thyroid hormones, and decrease in renal or hepatic insufficiency, when taken together with monoamine oxidase inhibitors, beta-blockers.
Ultratard HM (Ultratard nm) side effects:
Lipodystrophy (decrease in the volume of adipose tissue in the subcutaneous tissue), insulin resistance (lack of response to insulin administration), hypersensitivity reactions to the product are minimal.